Jonathan N. Thon

Founder/CEO | Board Member | Cell & Gene Therapy

[Jonathan N. Thon @JonathanThon]

https://t.co/nfJCtFgUu0 via @ua_magazine

[Jonathan N. Thon @JonathanThon]

2023 Reflections and Outlook for 2024 https://t.co/NoWKJiA7XW

[Jonathan N. Thon @JonathanThon]

https://t.co/2kIV6qRQFM

[Jonathan N. Thon @JonathanThon]

Tactically Engaging Your Scientific Advisory Board (SAB), by @bios_community https://t.co/OXxqlyLEYm

[Jonathan N. Thon @JonathanThon]

https://t.co/5E7fJtgbS5 CEO Jonathan Thon, Ph.D. to Deliver the 2023 R. D. Zeigler Innovation Research Lecture Sponsored by the V... https://t.co/HuMwAu6637

[Jonathan N. Thon @JonathanThon]

Tactically Engaging Your Scientific Advisory Board (SAB), by @bios_community https://t.co/OXxqlyLEYm

[Jonathan N. Thon @JonathanThon]

https://t.co/5E7fJtfE2x Presents Preclinical Data on a Novel Bone Marrow/HSPC-Targeted, Megakaryocyte-Derived Extracellular Vesicle Delivery Platform for In Vivo Gene Therapy at the Cell & Gene Meeting on the Mesa | BioSpace https://t.co/5ie5gcMjDL #jobs

[Jonathan N. Thon @JonathanThon]

https://t.co/5E7fJtfE2x Receives Extension of Grant to Advance In Vivo Gene Therapy Delivery Platform https://t.co/5RyVRmxUmb

[Jonathan N. Thon @JonathanThon]

https://t.co/5E7fJtfE2x to Present at 2023 Cell & Gene Meeting on the Mesa https://t.co/K9xZ5RIbKm

[Jonathan N. Thon @JonathanThon]

Why Repeatability of Dosing Matters for Gene Delivery https://t.co/smd8zgviyL

[Jonathan N. Thon @JonathanThon]

Inspiring the Next Generation of Entrepreneurs https://t.co/UxWry6HSyN

[Jonathan N. Thon @JonathanThon]

https://t.co/5E7fJtfE2x Appoints Independent Director Minnie Mildwoff, to its Board of Directors https://t.co/OTZ0ulXhgW

[Jonathan N. Thon @JonathanThon]

Cellular shuttle systems, by @ElliotHershberg https://t.co/QUyCaoFFTg

[Jonathan N. Thon @JonathanThon]

A mental-health crisis is gripping science — toxic research culture is to blame https://t.co/YG1MTu6Qap

[Jonathan N. Thon @JonathanThon]

Financing in a Challenging Environment https://t.co/ALTad1B3OA

[Jonathan N. Thon @JonathanThon]

Confronting Challenges in Developing Cell and Gene Therapies https://t.co/EbbrPd1Spa via @clinicalomics

[Jonathan N. Thon @JonathanThon]

https://t.co/5E7fJtfE2x Appoints Independent Director Dawn Bell, PharmD, to its Board https://t.co/et75I6nJKS

[Jonathan N. Thon @JonathanThon]

Opinion #3: What Makes a Great Scientific Advisory Board (SAB)? by @bios_community https://t.co/508n2RCHQt

[Jonathan N. Thon @JonathanThon]

A Better Way Series, Part V: Microvesicles Allow Repeat Dosing https://t.co/rKldE0RwHE

[Jonathan N. Thon @JonathanThon]

A Better Way Series, Part IV: Microvesicles are a Safer Delivery Platform https://t.co/RTwyRoMEgv